HBA 2020 Woman of the Year Announced
The Healthcare Businesswomen’s Association (HBA) last night announced the 2020 Woman of the Year during a reception at the J.P. Morgan Healthcare Conference.
Dr. Sandra Horning, former chief medical officer and head of global product development, Genentech and Roche, will be recognized at the HBA’s 31st annual Woman of the Year event on 29 April in New York City.
The HBA Woman of the Year award honors a female senior executive whose accomplishments have resulted in significant contributions to the healthcare industry.
During her tenure at Genentech and Roche, Dr. Horning helped to bring 15 new medicines to patients in neuroscience, ophthalmology, immunology, infectious disease and hematology/oncology. Driving for early access to life-saving medicines, she collaborated with the FDA and others in breakthrough therapy designation and early endpoints for regulatory approval. As a distinguished clinical investigator, she has been recognized as a global leader in the field of hematology/oncology and a respected clinician and scientist at the cutting edge of cancer research.
Beyond her contributions to medicine, Dr. Horning has been a passionate advocate for women in leadership both in the academy and in the office. During her tenure, gender parity increased across product development at Genentech and Roche at the senior leadership level. Currently, all five global product development sites at Genentech and Roche are led by women.
Look out for Pharm Exec’s cover profile of Dr. Sandra Horning in the April 2020 issue.
Sanofi Bolsters Immunology Pipeline with Acquisition of Dren Bio’s DR-0201 for Up to $1.9 Billion
March 20th 2025DR-0201, a CD20-directed bispecific antibody, has demonstrated robust B-cell depletion in early clinical studies, showing promise in treating refractory B-cell-mediated autoimmune diseases.
The Misinformation Maze: Navigating Public Health in the Digital Age
March 11th 2025Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
Phase III Trials Show Povorcitinib Significantly Improves Hidradenitis Suppurativa Outcomes
March 19th 2025In the Phase III STOP-HS1 and STOP-HS2 trials, results show that patients treated with povorcitinib for hidradenitis suppurativa experienced a ≥50% reduction in the total abscess and inflammatory nodule count.
